Perspective Therapeutics, Inc. (CATX)

AMEXHealth CareMedical - DevicesSnapshot 2026-10-23

$1.61-28.76%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Perspective Therapeutics, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	67,144
EPS	—	-0.258
Annual ending 2026-12-31
Revenue	—	287,638
EPS	—	-0.973
Annual ending 2027-12-31
Revenue	—	341,682
EPS	—	-1.024

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Fund clinical milestones into late 2027	Perspective Therapeutics aims to fund clinical milestones into late 2027.	Intact	cash and investments fall short of funding clinical milestones into late 2027	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Manage and reduce operating losses	Management focuses on reducing operating losses, which were -$28.28M in 2026-Q1.	Broken	operating losses worsen or remain stagnant below -$28M over next year	Operating income: $-29.258M FY2026-Q4; GAAP. Published target: Operating losses improve from -$28.28M in 2026-Q1 toward less negative levels. Target period is not explicitly aligned with this observation. Source published Aug 10, 2026-29,258,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q4 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 9dba8d6f-e219-4fee-8151-ab6c4e175dd9. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Stabilize or grow revenue	A supporting condition in Perspective Therapeutics, Inc.'s published investment case. The stated target is Revenue decline less than -85% next year or stabilize.	Broken	revenue declines more than -85% next year	Revenue: $81,000 FY2026-Q2; GAAP. Published target: Revenue decline less than -85% next year or stabilize. Target and observation units differ. Source published Aug 10, 202681,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-1.02

$-1.10 → $-1.02 · observed estimates

FY2027 revenue$0.00B

$0.00B → $0.00B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-1.10	$448,699	7 / 7
2026-07-25	$-1.10	$448,699	7 / 7
2026-07-26	$-1.10	$448,699	7 / 7
2026-07-27	$-1.10	$448,699	7 / 7
2026-07-28	$-1.10	$448,699	7 / 7
2026-07-29	$-1.13	$487,540	6 / 11
2026-07-30	$-1.13	$487,540	6 / 11
2026-07-31	$-1.10	$448,699	7 / 7
2026-08-01	$-1.13	$487,540	6 / 11
2026-08-02	$-1.13	$487,540	6 / 11
2026-08-03	$-1.13	$487,540	6 / 11
2026-08-04	$-1.10	$448,699	7 / 7
2026-08-05	$-1.10	$448,699	7 / 7
2026-08-06	$-1.10	$448,699	7 / 7
2026-08-07	$-1.10	$448,699	7 / 7
2026-08-08	$-1.10	$448,699	7 / 7
2026-08-09	$-1.13	$487,540	6 / 11
2026-08-10	$-1.13	$487,540	6 / 11
2026-08-11	$-1.12	$487,540	6 / 11
2026-08-12	$-1.10	$448,699	7 / 7
2026-08-13	$-1.08	$471,500	7 / 10
2026-08-14	$-1.10	$448,699	7 / 7
2026-08-15	$-1.10	$448,699	8 / 7
2026-08-16	$-1.10	$448,699	7 / 8
2026-08-17	$-1.10	$448,699	7 / 8
2026-08-18	$-1.10	$448,699	7 / 8
2026-08-19	$-1.10	$448,699	7 / 8
2026-08-20	$-1.10	$448,699	8 / 8
2026-08-21	$-1.03	$344,848	9 / 9
2026-08-22	$-1.03	$344,848	9 / 9
2026-08-23	$-1.03	$344,848	9 / 9
2026-08-24	$-1.03	$344,848	9 / 9
2026-08-25	$-1.03	$344,848	9 / 9
2026-08-26	$-1.03	$344,848	9 / 9
2026-08-27	$-1.03	$344,848	9 / 9
2026-08-28	$-1.03	$344,848	9 / 9
2026-08-29	$-1.03	$344,848	9 / 9
2026-08-30	$-1.03	$344,848	9 / 9
2026-08-31	$-1.01	$376,198	9 / 9
2026-09-01	$-1.01	$376,198	8 / 9
2026-09-02	$-1.01	$376,198	8 / 9
2026-09-03	$-1.01	$376,198	8 / 8
2026-09-04	$-1.01	$376,198	8 / 8
2026-09-05	$-1.01	$376,198	8 / 8
2026-09-06	$-1.01	$376,198	8 / 8
2026-09-07	$-1.01	$376,198	8 / 8
2026-09-08	$-1.01	$376,198	8 / 8
2026-09-09	$-1.01	$376,198	8 / 8
2026-09-10	$-1.01	$376,198	8 / 8
2026-09-11	$-1.01	$376,198	8 / 8
2026-09-12	$-1.01	$376,198	8 / 8
2026-09-13	$-1.01	$376,198	8 / 8
2026-09-14	$-1.01	$376,198	8 / 8
2026-09-15	$-1.01	$376,198	8 / 8
2026-09-16	$-1.03	$376,198	8 / 8
2026-09-17	$-1.03	$376,198	8 / 8
2026-09-18	$-1.03	$376,198	8 / 8
2026-09-19	$-1.03	$376,198	8 / 8
2026-09-20	$-1.03	$344,848	9 / 9
2026-09-21	$-1.03	$344,848	9 / 9
2026-09-22	$-1.03	$344,848	9 / 9
2026-09-23	$-1.03	$344,848	9 / 9
2026-09-24	$-1.03	$344,848	9 / 9
2026-09-25	$-1.03	$344,848	9 / 9
2026-09-26	$-1.03	$344,848	9 / 9
2026-09-27	$-1.03	$344,848	9 / 9
2026-09-28	$-1.03	$344,848	9 / 9
2026-09-29	$-1.03	$344,848	9 / 9
2026-09-30	$-1.03	$344,848	9 / 9
2026-10-01	$-1.03	$344,848	9 / 9
2026-10-02	$-1.03	$344,848	9 / 9
2026-10-03	$-1.03	$344,848	9 / 9
2026-10-04	$-1.03	$344,848	9 / 9
2026-10-05	$-1.03	$344,848	9 / 9
2026-10-06	$-1.03	$344,848	9 / 9
2026-10-07	$-1.03	$344,848	9 / 9
2026-10-08	$-1.03	$344,848	9 / 9
2026-10-09	$-1.03	$344,848	9 / 9
2026-10-10	$-1.03	$344,848	9 / 9
2026-10-11	$-1.03	$344,848	9 / 9
2026-10-12	$-1.03	$344,848	9 / 9
2026-10-13	$-1.03	$344,848	9 / 9
2026-10-14	$-1.03	$344,848	9 / 9
2026-10-15	$-1.03	$344,848	9 / 9
2026-10-16	$-1.03	$344,848	9 / 9
2026-10-17	$-1.03	$344,848	9 / 9
2026-10-18	$-1.03	$341,682	9 / 9
2026-10-19	$-1.03	$341,682	9 / 9
2026-10-20	$-1.03	$341,682	9 / 9
2026-10-21	$-1.02	$341,682	9 / 9
2026-10-22	$-1.02	$341,682	9 / 9
2026-10-23	$-1.02	$341,682	9 / 9
2026-10-24	$-1.02	$341,682	9 / 9

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	14	1
2026-06-01	14	1
2026-07-01	14	1
2026-08-01	15	1
2026-09-01	15	1
2026-10-01	15	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 15 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Fund clinical milestones into late 2027Direct metric needs a verified mapping
Manage and reduce operating lossesPublished status: Broken
Stabilize or grow revenuePublished status: Broken

Next proof point

Nov 9, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.4%Typical daily move · historical

Downside history

-71.5%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Perspective Therapeutics, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

CATX is a high-risk, clinical-stage oncology company rather than an established earnings compounder. Its long-term thesis is in a watch state: management is advancing its lead program and reports funding planned work into late 2027, but delivery remains mixed and confidence in the evidence is low.

What's priced into Perspective Therapeutics, Inc.

The valuation model indicates a durable premium to peers, while its expectations-gap measure is elevated; these measures have low confidence. The evidence does not specify exactly what expectations the market assumes, so it is unclear whether the premium is supported by future clinical progress or leaves limited room for delays.

What the fundamentals likely do

Near term, CATX remains loss-making, and recent financial performance is neutral and below its industry cohort, despite earnings-beat events in May and August. The October update showed positive response and disease-control rates for VMT-α-NET and preparations for a Phase 3 trial expected to start in 2027, while cash and short-term investments were about $237 million at June 30, 2026, with management saying they cover planned milestones and operations into late 2027. Guidance cuts, weaker employment data, or continued peer misses are risks; the near-term miss-risk estimate is 39%, though its watch tier is quiet.

What Perspective Therapeutics, Inc. hinges on

The multi-year thesis depends on clinical progress, including whether Phase 3 preparations lead to the expected 2027 start, and whether funding remains adequate as milestones and operations proceed. Regional manufacturing investment is visible in higher property and equipment, but the evidence does not show a completed facility or measured capacity gains. In the near term, guidance and employment trends could weigh on the setup, while continued earnings strength and higher guidance from healthcare peers could support sector momentum.